PGS Array for Improved IVF Treatments
Wed, 05/07/2014 - 2:15pm
Oxford Gene Technology (OGT) launched a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilisation (IVF). The array detects chromosome number abnormalities (aneuploidy) across all 46 human chromosomes using DNA amplified from a single cell from an early-stage embryo. This allows selection of an embryo with a normal chromosomal content. The Single Cell Aneuploidy array is the first commercially available oligonucleotide aCGH product designed specifically for PGS. The array is sensitive enough to work with small amounts of amplified DNA from a single cell from an early-stage embryo. Unlike technologies such as fluorescence in situ hybridisation (FISH), the array can detect aneuploidies across the whole genome. The array allows eight samples to be run simultaneously, which is more than existing bacterial artificial chromosome (BAC) aneuploidy arrays, minimising sample-to-sample variation by reducing technical noise. The array is complemented by OGT’s CytoSure Interpret Software which analyses the data generated to produce simple, easy-to-use results. The ability to clearly identify aneuploidy is vital to make a confident and informed decision as to the chromosomal content of an embryo. The array has also been research-validated to investigate aneuploidies in first polar bodies, single blastomeres and trophectoderm biopsies.
Oxford Gene Technology, www.ogt.com/ivf.